Not Yet Recruiting PHASE1 INTERVENTIONAL 14-arm
NCT06679998
A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection (AAPB)
A Dose-increasing, Randomized, Double-blind, Placebo-controlled, Single-dose/multiple-dose Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection in Healthy Chinese Subjects.
Sponsor: Jiangsu Kanion Pharmaceutical Co., Ltd
Conditions
Acute Ischemic Stroke (AIS)
Interventions
Multiple dosing, AAPB for injection, intravenous drip Multiple dosing, placebo, IV drip Single dose, AAPB by injection, intravenous drip. Single dose, placebo, intravenous drip.
Updated 1 time since 2024 Last updated: Nov 6, 2024 Started: Nov 14, 2024 Primary completion: Jan 12, 2026 Completion: Mar 26, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Acute Ischemic Stroke (AIS) and is currently actively recruiting participants. Jiangsu Kanion Pharmaceutical Co., Ltd leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Jiangsu Kanion Pharmaceutical Co., Ltd
Data source: Jiangsu Kanion Pharmaceutical Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .